You have free access to this content

Cancer

Cover image for Vol. 119 Issue 5

1 March 2013

Volume 119, Issue 5

Pages 925–1115

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
      New breast cancer findings presented at CTRC-AACR Symposium (page 927)

      Carrie Printz

      Version of Record online: 19 FEB 2013 | DOI: 10.1002/cncr.27998

      • original image
    4. You have free access to this content
      3 subtypes of ovarian cancer identified (page 927)

      Carrie Printz

      Version of Record online: 19 FEB 2013 | DOI: 10.1002/cncr.27999

  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      On collegiality and role models (pages 928–930)

      Fadlo R. Khuri

      Version of Record online: 29 JAN 2013 | DOI: 10.1002/cncr.27950

      • original image

      In this editorial, Dr. Fadlo Khuri discusses the process of peer reviewing submissions to Cancer.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. Disease Site

      Chest and Lung Disease
      You have free access to this content
      Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma (pages 931–938)

      Kyuichi Kadota, Jun-ichi Nitadori, Inderpal S. Sarkaria, Camelia S. Sima, Xiaoyu Jia, Akihiko Yoshizawa, Valerie W. Rusch, William D. Travis and Prasad S. Adusumilli

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27863

      • original image
      • original image
      • original image
      • original image

      Thyroid transcription factor-1 expression appears to correlate with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in patients with stage I lung adenocarcinoma, and further stratifies patients with intermediate-grade histology into 2 prognostic subsets.

    2. Gastrointestinal Disease
      You have free access to this content
      Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response : A phase 2 study (pages 939–945)

      Felice Pasini, Giovanni de Manzoni, Andrea Zanoni, Antonio Grandinetti, Carlo Capirci, Michele Pavarana, Anna Tomezzoli, Domenico Rubello and Claudio Cordiano

      Version of Record online: 16 NOV 2012 | DOI: 10.1002/cncr.27822

      • original image
      • original image

      This phase 2 study sought to define the pathological response rate of a neoadjuvant schedule including weekly docetaxel and cisplatin, continuous infusion of fluorouracil, and concomitant radiotherapy in untreated stage II-III adenocarcinoma and squamous cell carcinoma of mid-distal thoracic esophagus. Results show that this intensive weekly schedule produced a high pathological response rate, and responders had high and long-term durable survival rates.

    3. Gynecologic Oncology
      You have free access to this content
      Methylation status of TUSC3 is a prognostic factor in ovarian cancer (pages 946–954)

      Dietmar Pils, Peter Horak, Petr Vanhara, Mariam Anees, Michaela Petz, Angela Alfanz, Alfred Gugerell, Michael Wittinger, Andreas Gleiss, Veronika Auner, Dan Tong, Robert Zeillinger, Elena-Ioana Braicu, Jalid Sehouli and Michael Krainer

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27850

      • original image

      Tumor suppressor candidate 3 (TUSC3), a putative tumor suppressor gene, is frequently down-regulated in ovarian cancer. The epigenetic silencing of TUSC3 is correlated with poor progression-free and overall survival in patients with ovarian cancer.

    4. You have free access to this content
      The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers : Implications for counseling (pages 955–962)

      Peggy M. L. H. Vencken, Mieke Kriege, Maartje Hooning, Marian B. Menke-Pluymers, Bernadette A. M. Heemskerk-Gerritsen, Lena C. van Doorn, Margriet M. Collée, Agnes Jager, Cees van Montfort, Curt W. Burger and Caroline Seynaeve

      Version of Record online: 16 NOV 2012 | DOI: 10.1002/cncr.27839

      • original image
      • original image

      In patients with breast cancer susceptibility gene (BRCA)-associated ovarian cancer, the risk of breast cancer is lower than in mutation carriers without ovarian cancer and is lower than the risk of dying from ovarian cancer. The current data may contribute to tailored counseling for these patients.

    5. Head and Neck Disease
      You have free access to this content
      Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels (pages 963–970)

      Wen-Yi Wang, Chih-Wen Twu, Hsin-Hong Chen, Rong-San Jiang, Ching-Te Wu, Kai-Li Liang, Yi-Ting Shih, Chien-Chih Chen, Po-Ju Lin, Yi-Chun Liu and Jin-Ching Lin

      Version of Record online: 12 OCT 2012 | DOI: 10.1002/cncr.27853

      • original image
      • original image
      • original image
      • original image

      In this expanded study, the results confirm the prognostic significance of plasma Epstein-Barr virus DNA levels using predefined cutoff values in an independent patient group and demonstrate that plasma Epstein-Barr virus DNA is an independent prognostic marker in patients with nasopharyngeal carcinoma after long-term follow-up.

    6. Hematologic Malignancies
      You have free access to this content
      Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma : A multicenter, open label phase 1/2 study (pages 971–977)

      Maria Teresa Petrucci, Anna Levi, Sara Bringhen, Simona Scotti, Fabiana Gentilini, Simone Russo, Agostina Siniscalchi, Alessandra Larocca, Sara Grammatico, Mario Boccadoro, Robin Foà and Antonio Palumbo

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27820

      • original image
      • original image

      The results from this study demonstrate that bortezomib and melphalan can be administered safely and effectively to elderly patients with relapsed/refractory multiple myeloma. The schedule is specially tailored for elderly patients who are not eligible for intensive treatment and who require the assurance of an advantage in terms of response and survival and along with an associated low rate of toxicity.

    7. You have free access to this content
      Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia : Nine years of experience at a single center (pages 978–985)

      Yu Wang, Dai-Hong Liu, Kai-Yan Liu, Lan-Ping Xu, Xiao-Hui Zhang, Wei Han, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Jing-Zhi Wang, Yu-Qian Sun and Xiao-Jun Huang

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27761

      • original image
      • original image
      • original image

      This long-term follow-up study concluded that transplantation of granulocyte colony-stimulating factor–primed peripheral blood stem cells and bone marrow from human leukocyte antigen (HLA)-mismatched/haploidentical related donors by the regimen developed by the authors is reliable for leukemia patients. Thus, it provides an opportunity for patients to benefit from hematopoietic stem cell transplantation when an HLA-matched donor is not available.

    8. You have free access to this content
      Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases (pages 986–992)

      Roberto Crocchiolo, Benjamin Esterni, Luca Castagna, Sabine Fürst, Jean El-Cheikh, Raynier Devillier, Angela Granata, Claire Oudin, Boris Calmels, Christian Chabannon, Réda Bouabdallah, Norbert Vey and Didier Blaise

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27858

      • original image
      • original image
      • original image

      The use of antithymocyte globulin (ATG) in the conditioning regimen at a dose of 5 mg/kg significantly reduces the incidence and severity of acute and chronic graft-versus-host disease compared with an ATG dose of 2.5 mg/kg, among patients undergoing reduced-intensity conditioning transplantation for hematologic diseases without any evidence of impaired disease control. This conditioning represents a step forward in the optimization of a preparative regimen for reduced-intensity conditioning transplantation.

    9. Hepatobiliary Disease
      You have free access to this content
      High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery (pages 993–1003)

      Ruo-Yu Shi, Xin-Rong Yang, Qiu-Jin Shen, Liu-Xiao Yang, Yang Xu, Shuang-Jian Qiu, Yun-Fan Sun, Xin Zhang, Zheng Wang, Kai Zhu, Wen-Xin Qin, Zhao-You Tang, Jia Fan and Jian Zhou

      Version of Record online: 6 NOV 2012 | DOI: 10.1002/cncr.27788

      • original image
      • original image
      • original image
      • original image
      • original image

      Dickkopf-related protein 1 (DKK1) enhances intrahepatic cholangiocarcinoma invasion and promotes lymph node metastasis through the induction of matrix metalloproteinase 9 and vascular endothelial growth factor C. DKK1 may be a novel prognostic biomarker and a potential therapeutic target for intrahepatic cholangiocarcinoma.

    10. Neuro-Oncology
      You have free access to this content
      Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis (pages 1004–1012)

      Maurizio Martini, Tonia Cenci, Giorgio Quintino D'Alessandris, Valeriana Cesarini, Alessandra Cocomazzi, Lucia Ricci-Vitiani, Ruggero De Maria, Roberto Pallini and Luigi Maria Larocca

      Version of Record online: 6 NOV 2012 | DOI: 10.1002/cncr.27821

      • original image
      • original image
      • original image
      • original image
      • original image

      Id4 (inhibitor of DNA binding/differentiation type 4) epigenetic silencing identified a subgroup of glioblastoma with a favorable clinical outcome when treated with surgery followed by adjuvant radiotherapy and temozolomide. This effect may be due to involvement of Id4 in the MGP (matrix GLA protein)-mediated neoangiogenesis.

    11. Soft Tissue and Bone Sarcoma
      You have free access to this content
      Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma (pages 1013–1022)

      Hege O. Ohnstad, Russell Castro, Jinchang Sun, Karen-Marie Heintz, Lyubomir T. Vassilev, Bodil Bjerkehagen, Stine H. Kresse, Leonardo A. Meza-Zepeda and Ola Myklebost

      Version of Record online: 16 NOV 2012 | DOI: 10.1002/cncr.27837

      • original image
      • original image
      • original image
      • original image

      In a large collection of sarcomas, patients with TP53 wild-type tumors had improved survival and response to chemotherapy, in particular with the apoptosis-prone variant R72. MDM2 overexpression on a TP53 wild-type background, predicted good response to MDM2 antagonists, irrespective of R72P or SNP309 status.

    12. Discipline

      Clinical Trials
      You have free access to this content
      Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers (pages 1023–1032)

      Jhanelle E. Gray, Soner Altiok, Mark G. Alexandrow, Frank W. Walsh, Jian Chen, Michael J. Schell, Datchen Fritz Tai and Gerold Bepler

      Version of Record online: 12 OCT 2012 | DOI: 10.1002/cncr.27836

      • original image
      • original image
      • original image
      • original image

      This chemoprevention trial is the first using a non-US Food and Drug Administration-approved, oral, small-molecule–targeted agent. Although the primary endpoint has not been met, the results indicate that enzastaurin is tolerable for 6 months by 75% of participants with a 19% positive response rate in all metaplastic or dysplastic lesions post-treatment.

    13. You have free access to this content
      Percutaneous image-guided cryoablation of painful metastases involving bone : Multicenter trial (pages 1033–1041)

      Matthew R. Callstrom, Damian E. Dupuy, Stephen B. Solomon, Robert A. Beres, Peter J. Littrup, Kirkland W. Davis, Ricardo Paz-Fumagalli, Cheryl Hoffman, Thomas D. Atwell, J. William Charboneau, Grant D. Schmit, Matthew P. Goetz, Joseph Rubin, Kathy J. Brown, Paul J. Novotny and Jeff A. Sloan

      Version of Record online: 12 OCT 2012 | DOI: 10.1002/cncr.27793

      • original image
      • original image
      • original image

      Single-arm multicenter trial of the use of percutaneous cryoablation for palliation of focal painful metastatic tumors involving bone was conducted using the Brief Pain Inventory as a measure for treatment response. This image-guided treatment is a safe, effective, and durable method for palliation of pain due to metastatic disease involving bone.

    14. You have free access to this content
      Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma (pages 1042–1049)

      Manon Buijs, Diane K. Reyes, Timothy M. Pawlik, Amanda L. Blackford, Riad Salem, Wells A. Messersmith, Colin D. Weekes, Mary Mulcahy, Ihab R. Kamel and Jean-Francois H. Geschwind

      Version of Record online: 6 NOV 2012 | DOI: 10.1002/cncr.27859

      • original image
      • original image

      In this single-arm, phase 2 study of patients with unresectable hepatocellular carcinoma, the combination of bevacizumab and transhepatic arterial chemoembolization is safe in carefully selected patients and has antitumor activity.

    15. Disparities Research
      You have free access to this content
      Rural-urban disparities in health status among US cancer survivors (pages 1050–1057)

      Kathryn E. Weaver, Ann M. Geiger, Lingyi Lu, and L. Douglas Case

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27840

      There are an estimated 2.8 million cancer survivors who reside in rural areas of the United States. Relative to urban survivors, rural survivors report poorer health, higher psychological distress, more noncancer comorbidities, and higher rates of health-related unemployment.

    16. Outcomes Research
      You have free access to this content
      Short-term outcomes of craniotomy for malignant brain tumors in the elderly (pages 1058–1064)

      Andreea Seicean, Sinziana Seicean, Nicholas K. Schiltz, Nima Alan, Paul K. Jones, Duncan Neuhauser and Robert J. Weil

      Version of Record online: 12 OCT 2012 | DOI: 10.1002/cncr.27851

      The results from this prospective, multi-institutional study suggest that advanced age (≥75 years) is not a risk factor for postoperative morbidity and mortality in patients who undergo craniotomy for definitive resection of a malignant brain tumor.

    17. You have free access to this content
      Impact of oncology-related direct-to-consumer advertising : Association with appropriate and inappropriate prescriptions (pages 1065–1072)

      Gregory A. Abel, Kun Chen, Nathan Taback, Michael J. Hassett, Deborah Schrag and Jane C. Weeks

      Version of Record online: 6 NOV 2012 | DOI: 10.1002/cncr.27814

      • original image

      Breast cancer aromatase inhibitor (AI) therapy provides a valuable paradigm for studying the impact of direct-to-consumer advertising (DTCA) on appropriate versus inappropriate prescribing; AIs have received substantial DTCA, and because they should only be used in postmenopausal women, age can serve as a surrogate marker of appropriateness. This study characterized the association between monthly changes in DTCA spending for AIs and monthly changes in the proportion of new breast cancer hormonal therapy prescriptions represented by AIs. It was found that DTCA was associated with increases in appropriate prescriptions, but had no significant effect on inappropriate prescriptions.

    18. Pathology
      You have free access to this content
      Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy : Outcomes of prospective excision (pages 1073–1079)

      Melissa P. Murray, Chad Luedtke, Laura Liberman, Tatjana Nehhozina, Muzaffar Akram and Edi Brogi

      Version of Record online: 6 NOV 2012 | DOI: 10.1002/cncr.27841

      No consensus exists on the need to excise a radiologic-pathologic concordant breast lesion that yields classic lobular neoplasia at core-needle biopsy. This article details the findings and upgrade rate in a series of 72 consecutive lesions that underwent prospective excision.

    19. Radiation Oncology
      You have free access to this content
      The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms (pages 1080–1088)

      Radka Stoyanova, Niraj H. Pahlajani, Brian L. Egleston, Mark K. Buyyounouski, David Y. T. Chen, Eric M. Horwitz and Alan Pollack

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27857

      • original image
      • original image
      • original image
      • original image
      • original image

      There are no published randomized trials that address the impact of adding androgen-deprivation therapy (ADT) to dose-escalated, definitive radiotherapy (RT). Dual-linked nomograms that were developed by the authors allow for estimates of the effects of different lengths of ADT on the outcome of patients who receive different RT doses. The results indicate that adding ADT is more important than a modest RT dose escalation.

    20. You have free access to this content
      Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States (pages 1089–1097)

      B. Ashleigh Guadagnolo, Jinhai Huo, Kai-Ping Liao, Thomas A. Buchholz and Prajnan Das

      Version of Record online: 6 NOV 2012 | DOI: 10.1002/cncr.27835

      • original image
      • original image
      • original image

      The proportion of patients with metastatic cancer receiving radiation therapy in the last year of life remained stable from 2000 to 2007. However, significant trends toward more advanced radiation techniques were observed.

    21. Symptom Control and Palliative Care
      You have free access to this content
      Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials (pages 1098–1105)

      David Hui, Isabella Glitza, Gary Chisholm, Sriram Yennu and Eduardo Bruera

      Version of Record online: 6 NOV 2012 | DOI: 10.1002/cncr.27854

      Data from 18 symptom control interventional supportive care/palliative oncology trials indicated that the attrition rate was high and was associated with various patient characteristics such as minority race and a high baseline symptom burden. These findings have implications for future clinical trial design, including eligibility criteria and sample size calculation.

    22. Translational Research
      You have free access to this content
      Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer (pages 1106–1112)

      Marjun P. Duldulao, Wendy Lee, Rebecca A. Nelson, Joyce Ho, Maithao Le, Zhenbin Chen, Wenyan Li, Joseph Kim and Julio Garcia-Aguilar

      Version of Record online: 23 OCT 2012 | DOI: 10.1002/cncr.27862

      Specific polymorphisms in the genes x-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1), xeroderma pigmentosum group D (XPD), and tumor protein 53 (TP53) are associated with increased toxicity to neoadjuvant chemoradiation therapy (NT) in rectal cancer. Screening for these polymorphisms may help tailor treatment for patients by selecting therapies with the lowest risk of toxicity, thus increasing patient compliance.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
  5. Erratum

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      Erratum (page 1115)

      Version of Record online: 12 OCT 2012 | DOI: 10.1002/cncr.27870

      This article corrects:

SEARCH

SEARCH BY CITATION